Azitra, Inc. Operating Cash Flow
Azitra, Inc. (AZTR) reported Operating Cash Flow of -$5.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Azitra, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.29M.
- Azitra, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.48M.
- Azitra, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.89M.
- Azitra, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.44M.
- Azitra, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$11.22M.
- Azitra, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.18M.
- Azitra, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$7.36M.
- Azitra, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$8.35M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.77M 10-Q · filed 2026-08-12 | -$8.66M derived: sum of 3 quarters · filed 2026-08-12 | -$11.11M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$2.48M 10-Q · filed 2026-05-13 | -$5.37M derived: sum of 2 quarters · filed 2026-05-13 | -$7.81M derived: sum of 3 quarters · filed 2026-05-13 | -$10.63M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$5.34M derived: sum of 2 quarters · filed 2026-02-27 | -$8.15M derived: sum of 3 quarters · filed 2026-08-12 | -$11.22M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | -$2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.26M derived: sum of 2 quarters · filed 2026-08-12 | -$8.33M 10-Q · filed 2025-11-12 | -$10.92M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$2.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.89M 10-Q · filed 2026-08-12 | -$8.47M derived: sum of 3 quarters · filed 2026-08-12 | -$10.95M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$3.07M 10-Q · filed 2026-05-13 | -$5.66M derived: sum of 2 quarters · filed 2026-05-13 | -$8.13M derived: sum of 3 quarters · filed 2026-05-13 | -$10.24M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$5.06M derived: sum of 2 quarters · filed 2026-02-27 | -$7.16M derived: sum of 3 quarters · filed 2026-02-27 | -$10.18M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | -$2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$4.58M derived: sum of 2 quarters · filed 2025-11-12 | -$7.60M 10-Q · filed 2025-11-12 | -$10.14M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$5.12M 10-Q · filed 2025-08-11 | -$7.66M derived: sum of 3 quarters · filed 2025-08-11 | -$9.45M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | -$3.02M 10-Q · filed 2025-05-13 | -$3.02M 10-Q · filed 2024-05-09 | -$5.56M derived: sum of 2 quarters · filed 2025-05-13 | -$7.35M derived: sum of 3 quarters · filed 2025-05-13 | -$9.08M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$4.33M derived: sum of 2 quarters · filed 2025-02-24 | -$6.06M derived: sum of 3 quarters · filed 2025-02-24 | -$7.36M 10-K · filed 2025-02-24 | ||
| 2023-09-30 | -$1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.52M derived: sum of 2 quarters · filed 2024-11-12 | -$4.82M 10-Q · filed 2024-11-12 | -$4.78M 10-Q · filed 2023-11-14 | -$7.00M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$3.03M 10-Q · filed 2024-08-12 | -$5.20M derived: sum of 3 quarters · filed 2024-08-12 | -$7.29M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | -$1.30M 10-Q · filed 2024-05-09 | -$3.48M derived: sum of 2 quarters · filed 2024-05-09 | -$5.56M derived: sum of 3 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$4.26M derived: sum of 2 quarters · filed 2024-03-15 | -$8.35M 10-K · filed 2024-03-15 | |||
| 2022-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$6.18M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | -$4.09M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |